课题基金 / 基金详情

Structure-based discovery of dopamine D1 receptor selective small molecule ligands

Structure-based discovery of dopamine D1 receptor selective small molecule ligands
基于结构的多巴胺 D1 受体选择性小分子配体发现
批准号:
9797673
负责人:
Dan Feng
金额:
$67.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-01-01 至 2021-12-31

项目摘要

项目成果

Dan Feng的其他基金

相似基金

相关文献

中文摘要
翻译
多巴胺受体是G蛋白偶联受体(GPCRs)的一个家族,并且可以进一步分为 分为D1样(D1和D5)和D2样(D2,D3和D4)亚家族。在本提案中,我们重点关注D1 受体,其在脑中以高水平广泛表达。D1活性的调节与 治疗许多精神和神经疾病,如精神分裂症,注意力缺陷 多动症、抑郁症、帕金森病和药物成瘾。一个重要的战略, 这些疾病的治疗是用激动剂使D1活性回到正常水平, 拮抗剂或变构调节剂。许多D1激动剂和拮抗剂已经开发出来, 几十年的基于配体的努力。然而,它们的临床应用受到了它们的局限性。 药代动力学差,缺乏亚型选择性,以及常见的不良反应,而优化 由于这些化合物有限的化学多样性,基于这些化合物的合成被证明具有挑战性。 因此,强烈需要新的选择性D1受体拮抗剂、激动剂或变构剂, 调制器。该提案的目标是解决D1在各种活性状态下的晶体结构, 从虚拟物中鉴定化学上新的D1选择性激动剂、拮抗剂和变构调节剂 根据这些结构进行筛选。该提案的具体化部分将建立在以下方面的成功基础上: 通过ConfometRx在内部解决结构D1-Gs蛋白质复合物。我们会致力改善 解析现有结构并解析D1受体与其他激动剂结合的更多结构 (多巴胺或多巴胺样)、拮抗剂或从虚拟筛选鉴定的化合物。虚拟 该提案的筛选工作旨在鉴定化学上新颖的化合物, D1的正构位点和变构位点。我们还将努力 基于同源性建模的紧密同源物D5受体,因为目前没有真正的选择性 化合物来区分这两种亚型的功能。新型先导化合物将成为 实验验证并进行基于结构的优化。这项研究最终将 通过临床试验推进最有前途的化合物商业化,以创造D1特异性 副作用最小的药物,可能与一家大型制药公司合作。 该提案是对NIMH SBIR PA-14-172,研究脑源性脑损伤的新工具的回应。 心理健康研究中的GPCR(R43/R44),
英文摘要
Dopamine receptors are a family of G protein-coupled receptors (GPCRs), and can be further divided into D1-like (D1 and D5) and D2-like (D2, D3 and D4) subfamilies. In this proposal, we focus on D1 receptor, which is widely expressed in brain at high levels. Modulation of D1 activity is implicated in the treatment of many psychiatric and neurological disorders, such as schizophrenia, attention deficit hyperactivity disorder, depression, Parkinson's disease and drug addiction. One important strategy for the treatment of these diseases is to bring D1 activity back to a normal level with either agonists or antagonists, or allosteric modulators. Many D1 agonists and antagonists have been developed after decades of ligand-based efforts. However, their clinical applications have been greatly limited by their poor pharmacokinetics, lack of subtype selectivity, and common adverse effects, while the optimization based on these compounds are proven to be challenging due to their limited chemical diversity. Therefore there is a strong need for novel selective D1 receptor antagonists, agonists or allosteric modulators. The goal of this proposal is to solve the crystal structures of D1 in various activity states and identify chemically novel D1 selective agonists, antagonists and allosteric modulators from virtual screening based on these structures. The crystallization part of this proposal will build on the success of solving the structure D1-Gs protein complex internally by ConfometRx. We will aim to improve the resolution of the existing structure and solve more structures of D1 receptor bound to other agonists (dopamine or dopamine-like), antagonists or the compounds identified from virtual screening. Virtual screening efforts of this proposal will aim at identifying chemically novel compounds binding at the orthosteric site and allosteric site(s) of D1 based on the structures. We will also extend our efforts to its close homolog D5 receptor based on homology modeling, as currently there are no truly selective compounds to distinguish the function of these two subtypes. Novel lead compounds will be experimentally validated and subjected to structure-based optimization. This research will ultimately be commercialized by advancing the most promising compound through clinical trials to create a D1-specific drug with minimal side effects, likely in partnership with a large pharmaceutical company. This proposal is in response to the NIMH SBIR PA-14-172, Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R43/R44),
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DEVELOPING METHODS FOR CRYSTALLIZING FAMILY C GPCRS
  • 批准号:
    7802803
  • 项目类别:
  • 资助金额:
    $25.0万
  • 财政年份:
    2010
  • 负责人:
    Dan Feng
  • 依托单位:
DEVELOPING METHODS FOR CRYSTALLIZING FAMILY C GPCRS
  • 批准号:
    8729621
  • 项目类别:
  • 资助金额:
    $33.3万
  • 财政年份:
    2010
  • 负责人:
    Dan Feng
  • 依托单位:
DEVELOPING METHODS FOR CRYSTALLIZING FAMILY C GPCRS
  • 批准号:
    8528732
  • 项目类别:
  • 资助金额:
    $33.3万
  • 财政年份:
    2010
  • 负责人:
    Dan Feng
  • 依托单位:
DEVELOPING METHODS FOR CRYSTALLIZING FAMILY C GPCRS
  • 批准号:
    8022838
  • 项目类别:
  • 资助金额:
    $25.0万
  • 财政年份:
    2010
  • 负责人:
    Dan Feng
  • 依托单位:
海外基金